Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment
PHASE2CompletedINTERVENTIONAL
Enrollment
2
Participants
Timeline
Start Date
July 10, 2017
Primary Completion Date
February 18, 2019
Study Completion Date
February 18, 2019
Conditions
Advanced Gastric Adenocarcinoma
Interventions
DRUG
AZD6094
AZD6094 600MG qd
DRUG
Docetaxel
Docetaxel 60 mg/m2
Trial Locations (1)
135-710
Samsung Medical Center, Seoul
All Listed Sponsors
lead
Samsung Medical Center
OTHER
NCT02447380 - Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment | Biotech Hunter | Biotech Hunter